| 第一章 | 總則 | 2 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 4 | | 第三章 | 股份和註冊資本 | 5 | | 第四章 | 減資和回購股份 | 9 | | 第五章 | 股票和股東名冊 | 11 | | 第六章 | 股東的權利和義務 | 12 | | 第七章 | 股東會 | 18 | | 第八章 | 類別股東表決的特別程序 | 37 | | 第九章 | 董事會 | 40 | | 第十章 | 公司董事會秘書 | 51 | | 第十一章 | 公司總經理及副總經理 | 52 | | 第十二章 | 公司董事和高級管理人員的資格和義務 | 53 | | 第十三章 | 財務會計制度 | 57 | | 第十四章 | 利潤分配 | 57 | | 第十五章 | 內部審計 | 62 | | 第十六章 | 會計師事務所的聘任 | 63 | | 第十七章 | 保險 | 63 | | 第十八章 | 勞動管理和職工工會組織 | 64 | | 第十九章 | 公司的合併與分立 | 65 | | 第二十章 | 公司解散和清算 | 66 | | 第二十一章 | 公司章程的修訂程序 | 68 | ...

（於中華人民共和國註冊成立之股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （H股股份代碼：00874） 於2025年9月26日舉行之2025年第二次臨時股東大會之投票結果 董事會欣然宣佈臨時股東大會已於2025年9月26日（星期五）舉行，且所有提交股東審議和批准之 議案經由有權出席臨時股東大會並於會上投票之股東投票表決後均已獲正式通過。 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）(i)一份日期為2025年9月5日之關於召開2025年 第二次臨時股東大會（「臨時股東大會」）的通告；及(ii)一份日期為2025年9月5日之臨時股東大會通函 （「通函」）。除非文義另有所指外，否則本公告所用詞彙的涵義與通函所界定者相同。 董事會欣然宣佈臨時股東大會已於2025年9月26日（星期五）舉行，且所有提交股東審議和批准之議案 經由有權出席臨時股東大會並於會上投票之股東投票表決後均已獲正式通過。 1. 緒言 1 (1) 臨時股東大會已於202 ...

Core Insights - Guangzhou Pharmaceutical Group Co., Ltd. (referred to as "Guangyao Group") has established a joint venture named Guangzhou Baiyunshan (600332) Xihe Health Pharmaceutical Co., Ltd. (referred to as "Baiyunshan Xihe Health") with the Xiamen Rare Earth Research Institute to enter the nuclear medicine sector [1][2] - Nuclear medicine, which involves radioactive drugs for diagnosis and treatment, is becoming a strategic focus for the global biopharmaceutical industry, with major pharmaceutical companies investing in this area [1] - The Chinese government has introduced policies to support the development of the nuclear medicine industry, including the "Medical Isotope Medium and Long-term Development Plan (2021-2035)" [1] Company Developments - Baiyunshan Xihe Health was established on August 15 with a registered capital of 50 million yuan, co-funded by Guangyao Group and the Xiamen Rare Earth Research Institute [2] - The technical team of Baiyunshan Xihe Health successfully produced high-quality Zirconium-89 using an advanced domestic solid target system, filling a gap in domestic production [2] - Guangyao Group has set clear goals: short-term focus on rapid industrialization of rare earth diagnostic and therapeutic nuclear products; mid-term plans to build a nuclear production and R&D base; and long-term commitment to providing smart nuclear medical solutions [2]

Core Viewpoint - The "2025 Phoenix Star Listed Company Awards" ceremony was held in Guangzhou, recognizing companies for their performance in innovation, returns, responsibility, growth, brand influence, and globalization [1] Award Categories and Winners - The awards included categories such as Best Innovative Listed Company, Best Shareholder Return Listed Company, Most Socially Responsible Listed Company, Best Employer Award, Most Growth Potential Listed Company, Most Brand Influential Listed Company, Best Global Business Contribution Listed Company, Best Overseas Globalization Case, and Best IPO Company [1] - Six companies were awarded the title of "Most Brand Influential Listed Company": China Railway Construction Corporation, China Pacific Insurance, Guangzhou Baiyunshan Pharmaceutical, Yiling Pharmaceutical, Master Kong, and Haier Smart Home [1][3] Company Highlights - **China Railway Construction Corporation**: Recognized for its significant role in the "Belt and Road" initiative, operating in over 140 countries, and has been listed among the Fortune Global 500 for 19 consecutive years. The company emphasizes high-quality development and innovation in infrastructure [5][6] - **Master Kong**: Acknowledged for its long-term respect for consumers and commitment to quality. The company aims to promote Chinese culinary culture globally while focusing on technological upgrades and cultural heritage [8][9] - **China Pacific Insurance**: The company has a strong brand value and influence, providing comprehensive protection to 180 million customers. It has been ranked among the top five global insurance brands for several years [11] - **Guangzhou Baiyunshan Pharmaceutical**: As a World Fortune 500 company, it emphasizes high-quality products and social responsibility, with a brand value of 31.79 billion yuan, leading the pharmaceutical health sector in China [13] - **Haier Smart Home**: Transitioned from a home appliance leader to a smart living pioneer, serving over 1 billion users globally. The company focuses on technological innovation and sustainable development, holding the highest number of smart home invention patents for 13 consecutive years [15][16] - **Yiling Pharmaceutical**: Known for its innovative traditional Chinese medicine products, with 17 patented drugs, 11 of which are included in the national medical insurance directory. The company has successfully expanded its market presence in over 50 countries [17][18]

Group 1 - The core point of the article is that Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial information for its children's Xiao Chai Hu granules on the National Medical Products Administration's clinical trial registration and information public platform [2] Group 2 - The announcement was made on the evening of September 22 [2] - The registration of the clinical trial indicates progress in the development of the children's medication [2] - This development may enhance the company's product portfolio in the pediatric medicine sector [2]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has announced the initiation of Phase II clinical trials for its pediatric Xiaochaihu granules, which are primarily used for treating pediatric gastrointestinal colds [1] Group 1: Clinical Trial Information - The pediatric Xiaochaihu granules have recently been registered for Phase II clinical trials on the National Medical Products Administration's platform [1] - Guanghua Pharmaceutical received the clinical trial approval notice from the National Medical Products Administration in May 2023 [1] - The project has incurred approximately RMB 18.59 million in research and development expenses to date [1] Group 2: Market Context - There are currently no similar products for pediatric Xiaochaihu granules available in the domestic or international markets [1] - No sales data for comparable products is available domestically or internationally [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for its pediatric Xiaochaihu granules, focusing on the treatment of pediatric gastrointestinal colds [1] Group 1: Clinical Trial Information - The Phase II clinical trial is designed as a randomized, double-blind, parallel-controlled, multi-center study to evaluate the efficacy and safety of pediatric Xiaochaihu granules for treating pediatric gastrointestinal colds [1] - The pediatric Xiaochaihu granules are primarily used for treating pediatric gastrointestinal colds, specifically targeting the "邪犯少阳证" syndrome [1] Group 2: Regulatory Approvals - Guanghua Pharmaceutical received the clinical trial approval notice from the National Medical Products Administration in May 2023 [1] - Following the approval, the company completed the ethical review and obtained the ethical approval to proceed with the Phase II clinical trial of pediatric Xiaochaihu granules [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for its pediatric Xiaochaihu granules, focusing on the treatment of pediatric gastrointestinal colds [1] Group 1: Clinical Trial Information - The clinical trial is designed as a randomized, double-blind, parallel-controlled, multi-center Phase II study [1] - The primary focus of the trial is to evaluate the efficacy and safety of pediatric Xiaochaihu granules in treating pediatric gastrointestinal colds (邪犯少阳证) [1] Group 2: Regulatory Approvals - Guanghua Pharmaceutical received the Drug Clinical Trial Approval Notice from the National Medical Products Administration in May 2023 [1] - Following the approval, the company completed the ethical review and obtained the ethical approval to proceed with the Phase II clinical trial [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥物進入II期臨床試驗的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年9月22日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"公司"）子公司广州白云山光 华制药股份有限公司（"光华药业"）研发的儿童小柴胡颗粒于近日在国 家药品监督管理局药物临床试验登记与信息公示平台公示了I ...

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for its pediatric Xiao Chai Hu granules on the National Medical Products Administration's clinical trial registration platform, focusing on the efficacy and safety of the treatment for pediatric gastrointestinal colds [1] Group 1 - The clinical trial is designed as a randomized, double-blind, parallel-controlled, multi-center Phase II study [1] - The study aims to evaluate the effectiveness and safety of pediatric Xiao Chai Hu granules in treating pediatric gastrointestinal colds with Shao Yang syndrome [1]